Dermatology
Conference Coverage
Clinicians still seek the best uses for apremilast
WAILEA, HAWAII – An expert calls apremilast outmatched for moderate to severe disease, but off-label use for moderate disease and other...
Conference Coverage
For optimal care, consider all acne in Latinos inflammatory
Postinflammatory hyperpigmentation is a common consequence of acne in Latinos, and it can be aggravated by medical treatments or procedures.
From the Journals
Racial differences in skin cancer risk after organ transplantation
Do dermatologists need to consider patients’ race when doing organ transplants?
Conference Coverage
How will crisaborole for atopic dermatitis fit into clinical practice?
WAILEA, HAWAII – Two pediatric dermatologists involved in studies of the topical PDE-4 inhibitor provide their views on this recently approved...
The Optimized Doctor
Machine learning melanoma
Can melanoma be diagnosed from an app? A Stanford University team believes so.
Conference Coverage
New 52-week EASI, pruritus data strengthen case for dupilumab in adult atopic dermatitis
ORLANDO – How can dupilumab improve symptoms and quality of life for patients with AD?
Conference Coverage
VIDEO: Working with alopecia patients’ insurers when using novel therapies
ORLANDO – Part of treating patients with alopecia areata is trying to obtain insurance coverage for promising treatments and screening for other...
Conference Coverage
When atopic dermatitis is really contact dermatitis
ATLANTA – What’s the best way to determine whether it’s atopic dermatitis or contact dermatitis?
Conference Coverage
Long-term peanut sublingual immunotherapy found safe
ATLANTA – Peanut sublingual immunotherapy induces clinically significant desensitization in the majority of subjects.
From the Journals
Psoriasis and depression may pack a PsA punch
What role might depression play in development of psoriatic arthritis?
Conference Coverage
For bullous pemphigoid, doxycycline noninferior to prednisolone, but safer
ORLANDO – Doxycycline effected a cure in 74% of patients with bullous pemphigoid in the BLISTER Trial.